David Dalvey Sells 20,000 Shares of Celcuity (NASDAQ:CELC) Stock

Celcuity, Inc. (NASDAQ:CELC) Director David Dalvey sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the completion of the sale, the director owned 90,000 shares of the company’s stock, valued at $10,802,700. This trade represents a 18.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Celcuity Stock Down 2.4%

CELC stock opened at $109.42 on Friday. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74. The company’s 50-day moving average price is $104.24 and its 200 day moving average price is $71.74. Celcuity, Inc. has a 52 week low of $7.57 and a 52 week high of $120.32. The company has a market cap of $5.06 billion, a P/E ratio of -29.81 and a beta of 0.25.

Celcuity (NASDAQ:CELC) last issued its earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.13. On average, research analysts expect that Celcuity, Inc. will post -2.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on CELC. Jefferies Financial Group upped their target price on Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. Needham & Company LLC set a $95.00 price objective on shares of Celcuity in a research note on Monday, October 20th. HC Wainwright restated a “neutral” rating and set a $94.00 target price (up from $77.00) on shares of Celcuity in a report on Monday, November 17th. Craig Hallum upped their price target on shares of Celcuity from $96.00 to $108.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Finally, Wells Fargo & Company began coverage on shares of Celcuity in a research report on Friday, December 12th. They issued an “overweight” rating and a $126.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $105.25.

Hedge Funds Weigh In On Celcuity

Several institutional investors and hedge funds have recently modified their holdings of CELC. WoodTrust Financial Corp grew its stake in Celcuity by 10.8% in the 4th quarter. WoodTrust Financial Corp now owns 6,207 shares of the company’s stock worth $619,000 after acquiring an additional 607 shares during the period. Jennison Associates LLC purchased a new position in shares of Celcuity during the 4th quarter worth $22,911,000. State of New Jersey Common Pension Fund D acquired a new stake in shares of Celcuity during the fourth quarter worth $433,000. Simplicity Wealth LLC purchased a new stake in shares of Celcuity in the fourth quarter valued at $580,000. Finally, M&T Bank Corp increased its stake in Celcuity by 14.3% in the fourth quarter. M&T Bank Corp now owns 4,671 shares of the company’s stock valued at $465,000 after purchasing an additional 583 shares during the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.